Publications by authors named "Donald J Pinto"

Claim this Profile
S
Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
James R Corte, Tianan Fang, Honey Osuna, Donald J P Pinto, Karen A Rossi

J Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.
James R Corte, Tianan Fang, Donald J P Pinto, Michael J Orwat, Alan R Rendina

Bioorg Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.
Donald J P Pinto, Joanne M Smallheer, James R Corte, Erin J D Austin, Cailan Wang

Bioorg Med Chem Lett· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
Michael J Orwat, Jennifer X Qiao, Kan He, Alan R Rendina, Joseph M Luettgen, Donald J P Pinto

Bioorg Med Chem Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.
Donald J P Pinto, Jennifer X Qiao, Robert M Knabb

Expert Opin Ther Pat· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.
Kan He, Joseph M Luettgen, Donglu Zhang, Bing He, James E Grace, Donald J P Pinto

Eur J Drug Metab Pharmacokinet· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
Joseph M Luettgen, Robert M Knabb, Kan He, Donald J P Pinto, Alan R Rendina

J Enzyme Inhib Med Chem· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.
Pancras C Wong, Donald J P Pinto, Donglu Zhang

J Thromb Thrombolysis· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factor Xa inhibitors: next-generation antithrombotic agents.
Donald J P Pinto, Joanne M Smallheer, Daniel L Cheney, Robert M Knabb, Ruth R Wexler

J Med Chem· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenyltriazolinones as potent factor Xa inhibitors.
Mimi L Quan, Donald J P Pinto, Karen A Rossi, Steven Sheriff, Richard S Alexander

Bioorg Med Chem Lett· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulfation of o-demethyl apixaban: enzyme identification and species comparison.
Lifei Wang, Nirmala Raghavan, Kan He, Joseph M Luettgen, W Griffith Humphreys, Donald J Pinto

Drug Metab Dispos· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations.
Kan He, Mingxin Qian, Harvey Wong, Stephen A Bai, Bing He, Donald J Pinto

J Pharm Sci· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
James R Corte, Tianan Fang, Donald J P Pinto, Wei Han, Zilun Hu

Bioorg Med Chem Lett· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
Jeffrey G Varnes, Dean A Wacker, Donald J P Pinto, Michael J Orwat, Jay P Theroff

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Donald J P Pinto, Michael J Orwat, Stephanie Koch, Karen A Rossi, Richard S Alexander

J Med Chem· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.
Jennifer X Qiao, Xuhong Cheng, Joanne M Smallheer, Robert A Galemmo, Spencer Drummond, Donald J P Pinto

Bioorg Med Chem Lett· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.
Donald J P Pinto, Robert A Galemmo, Mimi L Quan, Michael J Orwat, Charles Clark

Bioorg Med Chem Lett· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Donald J P Pinto, Michael J Orwat, Mimi L Quan, Qi Han, Robert A Galemmo

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Mimi L Quan, Patrick Y S Lam, Qi Han, Donald J P Pinto, Ming Y He

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lung volume reduction surgery on diaphragmatic neuromechanical coupling at 2 years.
Franco Laghi, Amal Jubran, Arzu Topeli, Patrick J Fahey, Edward R Garrity, Donald J de Pinto

Chest· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
James R Pruitt, Donald J P Pinto, Robert A Galemmo, Richard S Alexander, Karen A Rossi

J Med Chem· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
Patrick Y S Lam, Charles G Clark, Renhua Li, Donald J P Pinto, Michael J Orwat

J Med Chem· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma.
Henry J Pieniaszek, Anna F Davidson, Harry L Walton, Donald J Pinto, Richard E Olson

J Pharm Biomed Anal· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Pancras C Wong, Earl J Crain, Carol A Watson, Alverna M Zaspel, Matthew R Wright, Donald J P Pinto

J Pharmacol Exp Ther· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent.
Pancras C Wong, Donald J P Pinto, Robert M Knabb

Cardiovasc Drug Rev· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis